| Nov 8 |
Xilio Therapeutics reports Q3 results
|
| Nov 7 |
Xilio Therapeutics Announces Initial Clinical Trial Data from Phase 1C Dose Escalation for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Advanced Solid Tumors
|
| Nov 7 |
Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2024Â Financial Results
|
| Oct 30 |
Xilio Therapeutics to Present Initial Phase 1C Dose Escalation Data for XTX101 (Vilastobart) in Combination with Atezolizumab in a Late-Breaker Poster at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
|
| Oct 4 |
Xilio Therapeutics Announces Upcoming Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
|
| Oct 2 |
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
| Aug 28 |
Xilio Therapeutics to Present at Morgan Stanley 22nd Annual Global Healthcare Conference
|
| Aug 8 |
Xilio Therapeutics GAAP EPS of -$0.24, revenue of $2.4M
|
| Aug 8 |
Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2024 Financial Results
|
| Jun 29 |
Can Xilio Therapeutics (NASDAQ:XLO) Afford To Invest In Growth?
|
